Filtered By:
Drug: Methotrexate
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 5114 results found since Jan 2013.
Differentiating Keratoacanthoma From Squamous Cell Carcinoma: Are We Losing the Battle or Our Bearings? - Comment on "Intralesional Methotrexate for Keratoacanthomas: A Case Series"
Actas Dermosifiliogr. 2023 Sep 14:S0001-7310(23)00734-2. doi: 10.1016/j.ad.2023.08.010. Online ahead of print.NO ABSTRACTPMID:37716500 | DOI:10.1016/j.ad.2023.08.010
Source: Actas Dermo-Sifiliograficas - September 16, 2023 Category: Dermatology Authors: P L ópez Sanz Miriam Fern ández-Parrado Eduardo Escario Travesedo Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
BMJ Open Respir Res. 2023 Sep;10(1):e001580. doi: 10.1136/bmjresp-2022-001580.ABSTRACTINTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).METHODS AND ANALYSIS: In this phase III, double-blind, ...
Source: Respiratory Care - September 14, 2023 Category: Respiratory Medicine Authors: Toby M Maher Shervin Assassi Arata Azuma Vincent Cottin Anna-Maria Hoffmann-Vold Michael Kreuter Justin M Oldham Luca Richeldi Claudia Valenzuela Marlies S Wijsenbeek Carl Coeck Christina Schlecker Florian Voss Daniel Wachtlin Fernando J Martinez Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
Astaxanthin prevent nephrotoxicity through Nrf2/HO-1 pathway
Can J Physiol Pharmacol. 2023 Sep 8. doi: 10.1139/cjpp-2023-0015. Online ahead of print.ABSTRACTRenal toxicity is one of the side effects of methotrexate (MTX). Therefore, this study explored the use of Astaxanthin, as a natural carotenoid, against MTX-induced nephrotoxicity emphasizing the changes in oxidative stress and the expression of nuclear factor (erythroid-derived 2)-like 2/heme oxygenase 1 (Nrf2/HO-1). During the ten days of the experiment, male Wistar rats in different groups received methotrexate (10 mg/kg) on days 6, 8, and 10 and three doses of astaxanthin (25, 50, and 75 mg/kg) on the entire course. Renal fa...
Source: Canadian Journal of Physiology and Pharmacology - September 8, 2023 Category: Drugs & Pharmacology Authors: Faezeh Lorestani Ahmad Movahedian Adel Mohammadalipour Mohammad Hashemnia Mohammad Hossein Aarabi Source Type: research
Dishevelled: An emerging therapeutic oncogene in human cancers
This study aimed to investigate the underlying molecular mechanism of DVL in cancer pathogenesis as well as to explore its importance in cancer diagnosis and prognosis as well as its role as a mediator in cancer chemotherapy.PMID:37683388 | DOI:10.1016/j.prp.2023.154793
Source: Pathology, Research and Practice - September 8, 2023 Category: Pathology Authors: Shadia Hamoud Alshahrani Nodir Rakhimov Arti Rana Hashem O Alsaab Ahmed Hjazi Mohaned Adile Munther Abosaooda Adeeb Abdulally Abdulhussien Alazbjee Ali Alsalamy Reza Mahmoudi Source Type: research
Astaxanthin prevent nephrotoxicity through Nrf2/HO-1 pathway
Can J Physiol Pharmacol. 2023 Sep 8. doi: 10.1139/cjpp-2023-0015. Online ahead of print.ABSTRACTRenal toxicity is one of the side effects of methotrexate (MTX). Therefore, this study explored the use of Astaxanthin, as a natural carotenoid, against MTX-induced nephrotoxicity emphasizing the changes in oxidative stress and the expression of nuclear factor (erythroid-derived 2)-like 2/heme oxygenase 1 (Nrf2/HO-1). During the ten days of the experiment, male Wistar rats in different groups received methotrexate (10 mg/kg) on days 6, 8, and 10 and three doses of astaxanthin (25, 50, and 75 mg/kg) on the entire course. Renal fa...
Source: Canadian Journal of Physiology and Pharmacology - September 8, 2023 Category: Drugs & Pharmacology Authors: Faezeh Lorestani Ahmad Movahedian Adel Mohammadalipour Mohammad Hashemnia Mohammad Hossein Aarabi Source Type: research
